Arrowhead Research Corporation (ARWR) Announces FDA Clearance to Initiate AdipotideTM Phase I Clinical Trial
1/4/2012 8:26:23 AM
PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in oncology and obesity, today announced that the Investigational New Drug Application (IND) for its first obesity drug candidate, AdipotideTM, was accepted by the U.S. Food and Drug Administration allowing the initiation of a clinical trial to test the safety of the compound. AdipotideTM specifically targets and kills blood vessels supplying white fat tissue. The Phase I clinical trial will be conducted by The University of Texas MD Anderson Cancer Center, which will bear the costs of the planned clinical trial.